PriceTargets.com logo

Beta Bionics - BBNX Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $23.20
  • Forecasted Upside: 114.81%
  • Number of Analysts: 11
  • Breakdown:
  • 1 Sell Ratings
  • 3 Hold Ratings
  • 6 Buy Ratings
  • 1 Strong Buy Ratings
$10.80 As of 03/19/2026 05:00 PM ET
▲ +0.17 (1.60%)

This chart shows the closing price for BBNX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Beta Bionics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BBNX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BBNX

Analyst Price Target is $23.20
▲ +114.81% Upside Potential
This price target is based on 11 analysts offering 12 month price targets for Beta Bionics in the last 3 months. The average price target is $23.20, with a high forecast of $33.00 and a low forecast of $14.00. The average price target represents a 114.81% upside from the last price of $10.80.

This chart shows the closing price for BBNX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 11 polled investment analysts is to moderate buy stock in Beta Bionics. This rating has held steady since February 2025, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/25/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/24/2024
  • 1 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
3/24/2025
  • 1 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
6/22/2025
  • 1 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
9/20/2025
  • 1 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
12/19/2025
  • 2 strong buy ratings
  • 6 buy ratings
  • 4 hold ratings
  • 1 sell ratings
Ratings as of
2/17/2026
  • 1 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
3/19/2026

Latest Recommendations

  • 1 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
2/18/2026Lake Street CapitalSet Target$20.00
2/18/2026Stifel NicolausLower TargetBuy ➝ Buy$25.00 ➝ $22.00
2/18/2026Robert W. BairdLower TargetNeutral ➝ Neutral$28.00 ➝ $14.00
2/9/2026UBS GroupUpgradeStrong-Buy
2/8/2026UBS GroupInitiated CoverageBuy$24.00
2/4/2026Stifel NicolausLower TargetBuy ➝ Buy$31.00 ➝ $25.00
2/2/2026Truist FinancialLower TargetBuy ➝ Buy$37.00 ➝ $25.00
1/26/2026TD CowenInitiated CoverageHold$17.00
1/15/2026The Goldman Sachs GroupReiterated RatingBuy ➝ Buy$25.00
1/9/2026Lake Street CapitalBoost TargetBuy ➝ Buy$35.00 ➝ $40.00
1/9/2026Bank of AmericaDowngradeBuy ➝ Neutral
1/5/2026Bank of AmericaBoost TargetBuy ➝ Buy$30.00 ➝ $33.00
12/29/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
12/22/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
12/18/2025Truist FinancialBoost TargetBuy ➝ Buy$32.00 ➝ $37.00
12/16/2025Robert W. BairdSet Target$28.00
12/15/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
12/8/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
12/1/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
11/25/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
11/19/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
11/13/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
10/29/2025Lake Street CapitalReiterated RatingBuy ➝ Buy$35.00
10/29/2025Stifel NicolausReiterated RatingBuy ➝ Buy$26.00 ➝ $31.00
10/29/2025The Goldman Sachs GroupBoost TargetBuy ➝ Buy$26.00 ➝ $33.00
10/29/2025Robert W. BairdSet Target$23.00
10/29/2025Truist FinancialReiterated RatingBuy ➝ Buy$28.00 ➝ $32.00
10/29/2025Piper SandlerReiterated RatingOverweight ➝ Overweight$26.00 ➝ $32.00
10/21/2025Stifel NicolausInitiated CoverageBuy$26.00
10/8/2025Weiss RatingsReiterated RatingSell (D) ➝ Sell (D)
10/1/2025The Goldman Sachs GroupSet TargetNeutral ➝ Buy$18.00 ➝ $26.00
10/1/2025The Goldman Sachs GroupUpgradeHold ➝ Buy$18.00 ➝ $26.00
9/27/2025Weiss RatingsReiterated RatingSell (D) ➝ Sell (D)
9/22/2025Truist FinancialBoost TargetBuy ➝ Buy$21.00 ➝ $28.00
7/30/2025Truist FinancialBoost TargetBuy ➝ Buy$18.00 ➝ $21.00
7/30/2025Robert W. BairdSet TargetNeutral ➝ Neutral$15.00 ➝ $17.00
6/16/2025Truist FinancialInitiated CoverageBuy$26.00
6/12/2025Lake Street CapitalInitiated CoverageBuy ➝ Buy$30.00
5/30/2025The Goldman Sachs GroupInitiated CoverageNeutral$16.00
5/30/2025Wolfe ResearchInitiated CoverageOutperform$20.00
2/24/2025Leerink PartnersUpgradeStrong-Buy
2/24/2025Bank of AmericaInitiated CoverageBuy
2/24/2025Lake Street CapitalInitiated CoverageBuy$30.00
2/24/2025Stifel NicolausInitiated CoverageBuy$25.00
2/24/2025Piper SandlerInitiated CoverageOverweight$26.00
2/24/2025Leerink PartnersInitiated CoverageOutperform$28.00
2/20/2025Robert W. BairdUpgradeHold
2/20/2025LADENBURG THALM/SH SHInitiated CoverageNeutral$20.00
2/20/2025Robert W. BairdInitiated CoverageNeutral$20.00
(Data available from 3/19/2021 forward)

News Sentiment Rating

0.73 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/21/2025
  • 6 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/20/2025
  • 3 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/20/2025
  • 3 very positive mentions
  • 14 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/19/2025
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/19/2025
  • 4 very positive mentions
  • 18 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
1/18/2026
  • 2 very positive mentions
  • 19 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
2/17/2026
  • 15 very positive mentions
  • 26 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/19/2026

Current Sentiment

  • 15 very positive mentions
  • 26 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Beta Bionics logo
Beta Bionics, Inc. is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.
Read More

Today's Range

Now: $10.80
Low: $10.43
High: $11.03

50 Day Range

MA: $13.89
Low: $10.11
High: $20.14

52 Week Range

Now: $10.80
Low: $8.89
High: $32.71

Volume

1,189,561 shs

Average Volume

1,061,146 shs

Market Capitalization

$479.30 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

5.6

Frequently Asked Questions

What sell-side analysts currently cover shares of Beta Bionics?

The following equities research analysts have issued research reports on Beta Bionics in the last twelve months: Bank of America Corporation, Lake Street Capital, Piper Sandler, Robert W. Baird, Stifel Nicolaus, TD Cowen, The Goldman Sachs Group, Inc., Truist Financial Corporation, UBS Group AG, Wall Street Zen, Weiss Ratings, and Wolfe Research.
View the latest analyst ratings for BBNX.

What is the current price target for Beta Bionics?

0 Wall Street analysts have set twelve-month price targets for Beta Bionics in the last year. Their average twelve-month price target is $23.20, suggesting a possible upside of 114.8%. Bank of America Corporation has the highest price target set, predicting BBNX will reach $33.00 in the next twelve months. Robert W. Baird has the lowest price target set, forecasting a price of $14.00 for Beta Bionics in the next year.
View the latest price targets for BBNX.

What is the current consensus analyst rating for Beta Bionics?

Beta Bionics currently has 1 sell rating, 3 hold ratings, 6 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for BBNX.

What other companies compete with Beta Bionics?

Other companies that are similar to Beta Bionics include Soleno Therapeutics, Artivion, AxoGen, Inspire Medical Systems and PROCEPT BioRobotics. Learn More about companies similar to Beta Bionics.

How do I contact Beta Bionics' investor relations team?

Beta Bionics' physical mailing address is 11 HUGHES, IRVINE, CA, 92618. The company's listed phone number is (949) 427-7785 and its investor relations email address is [email protected]. The official website for Beta Bionics is www.betabionics.com. Learn More about contacing Beta Bionics investor relations.